Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CASI vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: CASI 2 – 3 SRZN (1 Tie) Matrix Metrics: CASI 2 – 6 SRZN

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over CASI Pharmaceuticals, Inc. (CASI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CASI carries a Unified Composite Score of 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While CASI currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -333.1% operating margin) and revenue trajectory (+408.6% vs. -60.5% YoY).
  • Technical & Structure Timing Caution: CASI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CASI vs SRZN
CASI NASDAQ
CASI Pharmaceuticals, Inc. Ordinary Shares
Pharmaceutical Preparations
$0.21
-74.06% 1D
Market Cap $12.4M
TTM Revenue $27M
Forward P/E N/M
Beta / 30D Vol 0.95β · 240% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 40.0 Fund 44.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 18
RSI-14: 18.4 · SMA20: $0.84 · SMA50: $0.88
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93

6-Pillar Scorecard Institutional Category Breakdown (CASI 2 – 3 SRZN)

Columns: Metric · CASI · SRZN
1. Valuation Multiples CASI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.5x 52.1x
2. Growth & Scale SRZN
Revenue Growth (YoY) -60.5% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $27M $11M
Market Cap $12.4M $642.7M
3. Profitability & Quality CASI
Gross Margin 35.8% N/A
Operating Margin -333.1% -485.4%
Net Profit Margin -184.0% 0.0%
Return on Equity (ROE) -1094.5% -62.8%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$42M EBITDA -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage -1094.5% ROE $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (13th %ile)
Put/Call OI Skew N/A 21.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CASI (2) vs SRZN (6)
Institutional Metric CASI SRZN Criterion Row Edge
Market Capitalization
Scale
$12.4M $642.7M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-60.5% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-333.1% -485.4% Higher Margin CASI
Net Profit Margin
Profitability
-184.0% 0.0% Higher Margin SRZN
Return on Equity (ROE)
Capital Efficiency
-1094.5% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
0% ($0–$3) 63% ($13–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
0.95β · 240% Vol 1.29β · 73% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite CASI
Trailing 12M Revenue (USD)
Operating Scale
$27M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
35.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.5x EV/Rev N/M PEG · 52.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$42M EBITDA (-1094.5% ROE) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +111.85 pp
CASI: -78.83% · SRZN: +33.02%
3M Horizon SRZN +187.9 pp
CASI: -83.13% · SRZN: +104.77%
6M Horizon SRZN +182.93 pp
CASI: -82.71% · SRZN: +100.22%
1Y Horizon SRZN +182.93 pp
CASI: -82.71% · SRZN: +100.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CASI vs SRZN. Trailing 12-month operating profitability (CASI -333.1% vs SRZN -485.4%) and valuation multiples (CASI N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CASI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$27M
Gross Margin35.8%
Op. Margin-333.1%
ROE / Fwd P/E-1094.5% · N/M
SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CASI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CASI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CASI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.4M market capitalization and -333.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CASI vs SRZN Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over CASI Pharmaceuticals, Inc. (CASI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). CASI carries a Unified Composite Score of 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While CASI currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -333.1% operating margin) and revenue trajectory (+408.6% vs. -60.5% YoY). Technical & Structure Timing Caution: CASI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: CASI posts -60.5% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (35.8% gross margin, -333.1% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). On trailing 12-month operating scale, CASI generates $27M in USD-normalized revenue versus $11M for SRZN. In operating R&D and SG&A reinvestment, CASI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

CASI screens cheaper on headline valuation multiples. CASI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported EBITDA margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CASI (-1094.5% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CASI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 240% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.